Drug Profile
Diethylnorspermine
Alternative Names: BENSPM; CI 1006; DE 333; DENSPM; N-N-diethylnorspermineLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Nippon Kayaku; Sanofi; University of Toronto
- Class Antineoplastics; Polyamines; Small molecules
- Mechanism of Action Adenosylmethionine decarboxylase inhibitors; Ornithine decarboxylase inhibitors; Spermidine-spermine N1-acetyltransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Liver cancer; Psoriasis
Most Recent Events
- 23 Aug 2007 Discontinued - Phase-I for Cancer in Japan (IV)
- 28 Apr 2006 This compound is still in active development for Liver cancer
- 30 Jul 2004 Phase-I/II clinical trials in Liver cancer in USA (IV)